Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E14.05 EPS (ttm)4.10 Insider Own0.04% Shs Outstand2.83B Perf Week1.27%
Market Cap162.92B Forward P/E15.24 EPS next Y3.78 Insider Trans-21.72% Shs Float2.82B Perf Month-1.13%
Income11.92B PEG2.83 EPS next Q0.74 Inst Own75.70% Short Float1.14% Perf Quarter-7.08%
Sales42.24B P/S3.86 EPS this Y176.90% Inst Trans0.15% Short Ratio2.89 Perf Half Y5.40%
Book/sh17.08 P/B3.37 EPS next Y12.10% ROA11.70% Target Price63.85 Perf Year3.21%
Cash/sh5.56 P/C10.36 EPS next 5Y4.96% ROE24.80% 52W Range51.68 - 63.11 Perf YTD2.25%
Dividend1.80 P/FCF118.66 EPS past 5Y-6.30% ROI0.50% 52W High-8.73% Beta0.34
Dividend %3.13% Quick Ratio1.50 Sales past 5Y9.00% Gross Margin61.20% 52W Low11.46% ATR0.94
Employees70000 Current Ratio1.80 Sales Q/Q-7.40% Oper. Margin37.40% RSI (14)49.72 Volatility1.15% 1.37%
OptionableYes Debt/Eq0.44 EPS Q/Q876.90% Profit Margin28.20% Rel Volume0.71 Prev Close57.51
ShortableYes LT Debt/Eq0.38 EarningsApr 28 BMO Payout42.40% Avg Volume11.09M Price57.60
Recom2.50 SMA200.20% SMA500.03% SMA200-0.70% Volume7,863,543 Change0.16%
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Feb-04-11Reiterated UBS Buy $42 → $40
Jan-24-11Reiterated Deutsche Bank Buy $48 → $43
Jan-24-11Reiterated Barclays Capital Overweight $43 → $41
Apr-26-15 10:45AM  Apple & Other Earnings Expected To Dominate The Week Of April 27
09:15AM  7 DIJA Earnings Previews for This Week: Apple, Merck, Pfizer, Exxon, Visa, Chevron at 24/7 Wall St.
Apr-25-15 09:26AM  Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver Congress 2015 at noodls
04:03AM  Merck Wins German Innovation Award with Liquid Crystals at noodls
Apr-24-15 06:28PM  Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
05:36PM  AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
04:02PM  The week ahead: Berkshire's annual meeting
03:53PM  What to Watch in the Week Ahead and on Monday, April 27 Reuters
02:45PM  Johnson & Johnsons Revenues Take a Hit with Stronger Dollar
02:44PM  Johnson & Johnson Posts Earnings, Lowers EPS Guidance on April 14
02:18PM  The Fed, Apple and Kentucky Derby: What's on tap next week
01:28PM  Business events scheduled for the coming week
01:09PM  Parsing Patient Engagement: Better Compliance Or Better Decisions? at Forbes
10:36AM  Why Maternal Mortality Is Rising In The U.S. at Forbes
10:13AM  Merck: Hepatitis C Treatment Shows 95% Cure Rate at The Wall Street Journal
09:48AM  AbbVie Hepatitis C Drug Granted Priority FDA Review at The Wall Street Journal
07:34AM  Merck says experimental Hepatitis C treatment shows 95% cure rate at MarketWatch
07:00AM  Merck Announces Results from C-SURFER Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease CNW Group
06:36AM  Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni
01:00AM  Merck oral hepatitis C regimen shows 95 pct cure rate
01:00AM  Mercks Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection Business Wire
01:00AM  Mercks Hepatitis C Medicines May Challenge Gilead and AbbVie at Bloomberg
Apr-23-15 07:07PM  Merck Gets a Boost of 69% in AQR Capitals Portfolio
12:06PM  AQR Capital Enhances Pfizer Holdings by 33%
03:30AM  Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease Business Wire
12:36AM  Meet Pharmas Newest Movers and Shakers at The Wall Street Journal
Apr-22-15 09:22PM  Meet Pharma's Newest Movers and Shakers at The Wall Street Journal
01:00PM  Tekmira Ebola drug succeeds in small monkey study
09:14AM  Merck Gets Bullied in Norway With Remicade Price War at Bloomberg
08:00AM  Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal PR Newswire
Apr-21-15 06:05PM  Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
04:50PM  Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
11:00AM  MMR Vaccine and Autism: Yet Again, No Link Exists -- Even For Children At Risk For Autism at Forbes
08:30AM  Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress Business Wire
12:14AM  A Plant to Ease Muscle and Joint Pain at The Wall Street Journal
12:14AM  U.S. Stocks Bounce Back at The Wall Street Journal
Apr-20-15 07:05PM  Bristol-Myers, Merck Trial Data Bolster New Cancer Drug Class
06:26PM  Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog
06:07PM  AQR Capital Ups Stake in Johnson and Johnson
05:58PM  Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog
05:31PM  Bristol, Merck Cancer Drugs Strut Their Stuff at Investor's Business Daily
05:29PM  U.S. Stocks Bounce Back at The Wall Street Journal
05:17PM  New data boosts biotechs
04:08PM  MylanPerrigo Merger: What Are the Long-Term Growth Drivers?
01:55PM  Bristol-Myers combination melanoma treatment shows promise at Financial Times
09:48AM  Test May Show Merck Melanoma Drugs Success in Lung Cancer at Bloomberg
09:30AM  The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical - Press Releases
09:01AM  Immune System Drugs Melt Tumors In New Study, Leading A Cancer Revolution at Forbes
08:30AM  Roche Breast-Cancer Drug Challenges Merck in Immunotherapy Race at Bloomberg
08:28AM  TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors at noodls
08:28AM  TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors at noodls
08:28AM  PDF Add to Briefcase File is in Briefcase at noodls
08:10AM  Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer at noodls
08:04AM  TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors at noodls
08:02AM  Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer at noodls
08:00AM  TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors Business Wire
08:00AM  TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors GlobeNewswire
03:02AM  Merck Demonstrates Commitment to Corporate Responsibility at noodls
12:16AM  Mercks Keytruda Shows Improved Survival Odds in Melanoma at The Wall Street Journal
Apr-19-15 05:20PM  Merck Drug Shows Improved Odds for Melanoma Patients at The Wall Street Journal
02:56PM  Studies: Merck drug Keytruda effective against 3 cancers
12:45PM  Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting PR Newswire
12:45PM  Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting CNW Group
12:45PM  Early Findings with KEYTRUDA® (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting Business Wire
12:26PM  Merck's Keytruda shrinks lung cancer tumors, FDA approval sought
09:00AM  Merck Cancer Drug Shines Against Skin, Lung Cancer at Forbes
08:43AM  Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine at noodls
08:30AM  Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Pembrolizumab Presented at AACR Annual Meeting and Published in the New England Journal of Medicine PR Newswire
08:30AM  Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Pembrolizumab Presented at AACR Annual Meeting and Published in the New England Journal of Medicine CNW Group
08:30AM  Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine Business Wire
08:30AM  Pembrolizumab, Merck's Investigational anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab, an Anti-CTLA-4 Therapy, in a Phase 3 Study of Patients with Advanced Melan PR Newswire
08:30AM  Pembrolizumab, Merck's Investigational anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab, an Anti-CTLA-4 Therapy, in a Phase 3 Study of Patients with Advanced Melan CNW Group
08:30AM  Merck Seeks Expanded Approval of Keytruda Immunotherapy to Treat Lung Cancer at TheStreet
08:30AM  KEYTRUDA® (pembrolizumab), Mercks Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy... Business Wire
08:14AM  Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer at noodls
08:00AM  Merck files for FDA approval of Keytruda in lung cancer Reuters
08:00AM  Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer Business Wire
Apr-17-15 01:44PM  Biotech investors brace for updates on key drugs at CNBC
10:44AM  Bristol's Opdivo Scores Again Against Lung Cancer at Investor's Business Daily
09:08AM  Annual General Meeting Approves Dividend Increase at noodls
04:23AM  Merck Proposes Dividend Increase to AGM After a Year of Key Strategic Moves Foundation Set for Further Organic Growth at noodls
Apr-16-15 06:04PM  AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
05:26PM  Biotech giants present new data
04:01PM  The 4 Stocks That Weighed on the DJIA Thursday at 24/7 Wall St.
04:00PM  Stocks fail to hold momentum from oil gains; earnings eyed at CNBC
03:44PM  Big pharma M&A may keep booming, CEOs say at CNBC
02:12PM  Exciting time for drug breakthroughs: Merck CEO
01:05PM  Sigma-Aldrich exec leaving to head medical packaging company at bizjournals.com
11:41AM  How Marketing And Media Muddled The Truth About The Heart Drug Vytorin at Forbes
08:02AM  Alise Reicin Joins Merck Serono as Head of Global Clinical Development at noodls
Apr-15-15 05:00PM  Merck, NewLink Ebola Vaccine Enters Third Phase III Study - Analyst Blog
02:41PM  Ariad Pharmaceuticals, Inc. (ARIA), Amgen, Inc. (AMGN): How Sarissa Capitals Top Picks Beat the Market at Insider Monkey
09:29AM  AstraZeneca science is on the move, one year on from Pfizer bid
08:00AM  Merck Seronos Saizen Liquid can now be Stored up to one Week at Room Temperature at noodls
04:01AM  Living Innovation: Merck at the European Coatings Show 2015 at noodls
Apr-14-15 08:05PM  Diabetes Drugs Get Neither Restrictions Nor Endorsements From FDA Committee at Forbes
06:21PM  FDA panel backs safety updates for AstraZeneca, Takeda drugs Reuters
05:37PM  AstraZeneca, Takeda Diabetes Drugs Should Warn of Heart Risk at Bloomberg
04:01PM  The 4 Stocks That Lifted the DJIA on Tuesday at 24/7 Wall St.
03:06PM  FDA panel wants heart failure risk on AstraZeneca drugs
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, including antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HARRISON WILLIAM B JRDirectorApr 13Option Exercise33.835,000169,15011,400Apr 13 05:24 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM
Deese Willie AExe V-P & Pres. MMDJun 27Option Exercise27.8572,2902,013,164178,512Jun 30 04:23 PM
Deese Willie AExe V-P & Pres. MMDJun 27Sale58.2672,2904,211,254106,222Jun 30 04:23 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 14Sale55.9110,527588,5840May 14 02:48 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Option Exercise34.2012,876440,307345,927May 13 03:56 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Sale55.0010,220562,100335,707May 13 03:56 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 04Option Exercise0.0019,147019,147May 06 04:03 PM
Golestani ClarkEVP & Chief Info OfficerMay 04Option Exercise0.002,05109,278May 06 04:02 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 04Option Exercise0.009,300098,387May 06 04:02 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareMay 04Option Exercise0.005,470038,311May 06 04:02 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.004,240011,999May 06 04:02 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise0.009,8470132,660May 06 04:02 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 04Option Exercise0.004,103026,720May 06 04:02 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 04Option Exercise0.004,103020,828May 06 04:01 PM
Deese Willie AExe V-P & Pres. MMDMay 04Option Exercise0.007,6590109,671May 06 04:01 PM
FRAZIER KENNETH CChairman, President & CEOMay 04Option Exercise0.0041,0280351,522May 06 04:01 PM